ES2717942T3 - Microesferas de buprenorfina de alta carga de fármaco y método de producción de las mismas - Google Patents
Microesferas de buprenorfina de alta carga de fármaco y método de producción de las mismas Download PDFInfo
- Publication number
- ES2717942T3 ES2717942T3 ES14764439T ES14764439T ES2717942T3 ES 2717942 T3 ES2717942 T3 ES 2717942T3 ES 14764439 T ES14764439 T ES 14764439T ES 14764439 T ES14764439 T ES 14764439T ES 2717942 T3 ES2717942 T3 ES 2717942T3
- Authority
- ES
- Spain
- Prior art keywords
- buprenorphine
- microspheres
- dispersed phase
- prepared
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title claims description 119
- 229960001736 buprenorphine Drugs 0.000 title claims description 118
- 239000004005 microsphere Substances 0.000 title claims description 107
- 229940079593 drug Drugs 0.000 title claims description 40
- 239000003814 drug Substances 0.000 title claims description 40
- 238000000034 method Methods 0.000 title claims description 25
- 238000011068 loading method Methods 0.000 title description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 90
- 229920000642 polymer Polymers 0.000 claims description 81
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 72
- 239000000203 mixture Substances 0.000 claims description 61
- 238000009472 formulation Methods 0.000 claims description 42
- 239000002904 solvent Substances 0.000 claims description 26
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 24
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 19
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 239000006184 cosolvent Substances 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 13
- 239000012458 free base Substances 0.000 claims description 12
- 238000013268 sustained release Methods 0.000 claims description 11
- 239000012730 sustained-release form Substances 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 2
- 239000012071 phase Substances 0.000 description 70
- 239000000243 solution Substances 0.000 description 37
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 30
- 241000700159 Rattus Species 0.000 description 12
- 238000009826 distribution Methods 0.000 description 11
- 238000005538 encapsulation Methods 0.000 description 11
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 230000036470 plasma concentration Effects 0.000 description 9
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 8
- 239000002033 PVDF binder Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 238000007429 general method Methods 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 229920001600 hydrophobic polymer Polymers 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 239000003596 drug target Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229920001477 hydrophilic polymer Polymers 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 239000011859 microparticle Substances 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 238000004945 emulsification Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 229920000747 poly(lactic acid) Polymers 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- PJRSUKFWFKUDTH-JWDJOUOUSA-N (2s)-6-amino-2-[[2-[[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylsulfanylbutanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]propanoyl]amino]acetyl]amino]propanoyl Chemical compound CSCC[C@H](NC(=O)CN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(N)=O PJRSUKFWFKUDTH-JWDJOUOUSA-N 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 229960001889 buprenorphine hydrochloride Drugs 0.000 description 2
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 108010021753 peptide-Gly-Leu-amide Proteins 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000157049 Microtus richardsoni Species 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 208000018526 Narcotic-Related disease Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- RMRJXGBAOAMLHD-CTAPUXPBSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-CTAPUXPBSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 229940053209 suboxone Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/837,181 US9393211B2 (en) | 2013-03-15 | 2013-03-15 | High drug load buprenorphine microspheres and method of producing same |
| PCT/US2014/027982 WO2014143839A1 (en) | 2013-03-15 | 2014-03-14 | High drug load buprenorphine microspheres and method of producing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2717942T3 true ES2717942T3 (es) | 2019-06-26 |
Family
ID=51528078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14764439T Active ES2717942T3 (es) | 2013-03-15 | 2014-03-14 | Microesferas de buprenorfina de alta carga de fármaco y método de producción de las mismas |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9393211B2 (enExample) |
| EP (1) | EP2968577B1 (enExample) |
| JP (1) | JP6678571B2 (enExample) |
| CN (1) | CN105377301B (enExample) |
| BR (1) | BR112015022985A2 (enExample) |
| CA (1) | CA2904432A1 (enExample) |
| ES (1) | ES2717942T3 (enExample) |
| MX (1) | MX362709B (enExample) |
| WO (1) | WO2014143839A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| EP2152315B1 (en) | 2007-05-25 | 2016-01-06 | Indivior UK Limited | Sustained delivery formulations of risperidone compounds |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| ES2837803T3 (es) | 2012-07-26 | 2021-07-01 | Camurus Ab | Formulaciones de opioides |
| AU2013294915C1 (en) | 2012-07-26 | 2019-11-21 | Camurus Ab | Opioid formulations |
| US9636308B2 (en) * | 2013-03-15 | 2017-05-02 | Oakwood Laboratories LLC | High drug load buprenorphine microspheres and method of producing same |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| US20170065579A1 (en) * | 2015-09-08 | 2017-03-09 | Andreas Voigt | Sustained Release Low Dose Formulations and Uses Thereof |
| CN105596298B (zh) * | 2015-12-18 | 2018-08-14 | 山东大学 | 一种包载丁丙诺啡的peg-plga缓释微球及其制备方法 |
| CA3015488A1 (en) * | 2016-02-23 | 2017-08-31 | Biodelivery Sciences International, Inc. | Sustained release buprenorphine microspheres (srbm) and methods of use thereof |
| PL3512518T3 (pl) | 2016-09-13 | 2023-03-27 | Alar Pharmaceuticals Inc. | Preparaty buprenorfiny o przedłużonym uwalnianiu |
| TWI838372B (zh) | 2018-05-11 | 2024-04-11 | 昱展新藥生技股份有限公司 | 丁基原啡因衍生物之長效注射劑型及結晶型 |
| CN115605187B (zh) * | 2020-02-26 | 2024-09-17 | 福多兹制药公司 | 载有孕激素药物的可注射控释制剂 |
| CA3210098A1 (en) | 2021-02-24 | 2022-09-01 | Oakwood Laboratories, Llc | Microsphere formulations comprising lurasidone and methods for making and using the same |
| CN114392384B (zh) * | 2021-12-24 | 2023-04-11 | 河南驼人医疗器械研究院有限公司 | 一种制备高载药量栓塞微球的方法及收集装置 |
| CN115317453A (zh) * | 2022-09-01 | 2022-11-11 | 广东嘉博制药有限公司 | 一种缓释微球制剂及其制备方法与用途 |
| EP4611729A1 (en) * | 2022-10-31 | 2025-09-10 | Oakwood Laboratories, LLC | Mixed release profile polymer microsphere formulations comprising octreotide and methods for making and using the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5026556A (en) | 1988-11-10 | 1991-06-25 | Norwich Eaton Pharmaceuticals, Inc. | Compositions for the transdermal delivery of pharmaceutical actives |
| CA2382577C (en) | 1999-08-27 | 2008-01-22 | Southern Research Institute | Injectable buprenorphine microparticle compositions and their use |
| EP1555023A3 (en) * | 1999-08-27 | 2005-09-28 | Southern Research Institute | Injectable buprenorphine microparticle compositions and their use |
| US7041320B1 (en) | 2002-05-31 | 2006-05-09 | Biotek, Inc. | High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence |
| US20050048115A1 (en) | 2003-08-27 | 2005-03-03 | Murty Mangena | Buprenorphine microspheres |
| TWI362947B (en) | 2007-03-08 | 2012-05-01 | Univ Kaohsiung Medical | Controlled release pharmaceutical composition and manufacture method thereof |
| US9161943B2 (en) | 2007-12-31 | 2015-10-20 | Industrial Technology Research Institute | Sustained release composition and manufacturing method thereof |
| KR101113044B1 (ko) * | 2008-08-29 | 2012-02-27 | 동국제약 주식회사 | 용매교류증발법에 의한 서방출성 미립구의 제조방법 |
| US20100086597A1 (en) | 2008-10-06 | 2010-04-08 | Oakwood Laboratories LLC | Microspheres for the sustained release of octreotide with a low initial burst |
| WO2011087496A1 (en) | 2010-01-13 | 2011-07-21 | Oakwood Laboratories LLC | Microspheres for the sustained release of octreotide without an initial time lag |
| GB2481018B (en) | 2010-06-08 | 2015-03-18 | Rb Pharmaceuticals Ltd | Injectable flowable composition comprising buprenorphine |
-
2013
- 2013-03-15 US US13/837,181 patent/US9393211B2/en active Active
-
2014
- 2014-03-14 BR BR112015022985A patent/BR112015022985A2/pt not_active IP Right Cessation
- 2014-03-14 CA CA2904432A patent/CA2904432A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/027982 patent/WO2014143839A1/en not_active Ceased
- 2014-03-14 JP JP2016502675A patent/JP6678571B2/ja active Active
- 2014-03-14 ES ES14764439T patent/ES2717942T3/es active Active
- 2014-03-14 CN CN201480021351.9A patent/CN105377301B/zh active Active
- 2014-03-14 MX MX2015012232A patent/MX362709B/es active IP Right Grant
- 2014-03-14 EP EP14764439.7A patent/EP2968577B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2904432A1 (en) | 2014-09-18 |
| JP6678571B2 (ja) | 2020-04-08 |
| US9393211B2 (en) | 2016-07-19 |
| JP2016513721A (ja) | 2016-05-16 |
| MX2015012232A (es) | 2015-12-01 |
| CN105377301B (zh) | 2020-06-05 |
| MX362709B (es) | 2019-02-05 |
| CN105377301A (zh) | 2016-03-02 |
| EP2968577A1 (en) | 2016-01-20 |
| EP2968577A4 (en) | 2016-11-23 |
| US20140271869A1 (en) | 2014-09-18 |
| BR112015022985A2 (pt) | 2017-08-22 |
| WO2014143839A1 (en) | 2014-09-18 |
| EP2968577B1 (en) | 2019-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6678571B2 (ja) | 高薬物含有ブプレノルフィンマイクロスフェア及びその製造方法 | |
| US9636308B2 (en) | High drug load buprenorphine microspheres and method of producing same | |
| ES2391315T5 (es) | Método para preparar micropartículas que tienen un peso molecular polimérico seleccionado | |
| EP2968320B1 (en) | Organic compounds | |
| ES2755032T3 (es) | Formulación de liberación sostenida que comprende octreótido y dos o más polímeros de poliláctido-co-glicólido | |
| JP2016527308A (ja) | エンテカビル微小球及びこれを含む非経口投与用医薬組成物 | |
| ES2738999T3 (es) | Método de preparación de micropartículas de liberación sostenida que contienen medicamentos | |
| US20220265562A1 (en) | Microsphere formulations comprising lurasidone and methods for making and using the same | |
| US12233165B2 (en) | Microsphere formulations comprising ketamine and methods for making and using the same | |
| US20240216280A1 (en) | Microsphere formulations comprising nalmefene andmethods for making and using the same | |
| ES3061392T3 (en) | Microsphere formulations comprising ketamine and methods for making and using the same | |
| Joshi et al. | Optimization of Chitosan-wrapped Linagliptin Nanosuspension for Cognitive Enhancement Through Intranasal Route | |
| US20240307381A1 (en) | Microsphere formulations comprising lurasidone and methods for making and using the same | |
| US20250032451A1 (en) | Microsphere formulations comprising asenapine and methods for making and using the same | |
| JP2026507990A (ja) | オクトレオチドを含む混合放出プロファイルポリマーミクロスフェア製剤ならびにその製造方法及び使用方法 | |
| US20230225993A1 (en) | Microsphere formulations comprising ketamine and methods for making and using the same | |
| WO2025117624A1 (en) | Microsphere formulations comprising brexpiprazole and methods for making and using the same | |
| CN116916893A (zh) | 包含btk抑制剂的微球制剂及其制备和使用方法 | |
| CN116916920A (zh) | 包含鲁拉西酮的微球制剂及其制备和使用方法 | |
| EP4658272A1 (en) | Microsphere formulations comprising naltrexone and methods for making and using the same |